Gastrointestinal Stromal Tumors (GIST) Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Scienc

Gastrointestinal Stromal Tumors (GIST) Pipeline constitutes 25+ key companies continuously working towards developing 28+ Gastrointestinal Stromal Tumors (GIST) treatment therapies, analyzes DelveInsight.

Gastrointestinal Stromal Tumors (GIST) Overview:

Gastrointestinal Stromal Tumors (GISTs) are a type of cancer classified under sarcomas-a group of malignant tumors that develop from connective tissues such as fat, muscle, nerves, cartilage, bone, blood vessels, and lymphatic vessels. This sets sarcomas apart from other cancers like carcinomas, which originate in the lining of organs or tissues (such as the lungs, colon, breast, prostate, and pancreas), lymphomas, which begin in immune cells within the lymph nodes, and leukemias, which arise from immune cells in the bone marrow.

GISTs can cause a wide range of symptoms. These may include subjective experiences such as nausea, feeling full quickly, bloating, and unexplained weight loss. In addition, patients might display physical signs like anemia (a decrease in red blood cells) or a noticeable mass in the abdomen. The specific symptoms and signs vary depending on the tumor's location (for example, in the stomach or rectum), its size, and how it grows.

Download our report @ https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Gastrointestinal Stromal Tumors (GIST) Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Gastrointestinal Stromal Tumors (GIST) Therapeutics Market.

Key Takeaways from the Gastrointestinal Stromal Tumors (GIST) Pipeline Report

DelveInsight's Gastrointestinal Stromal Tumors (GIST) pipeline report depicts a robust space with 25+ active players working to develop 28+ pipeline therapies for Gastrointestinal Stromal Tumors (GIST) treatment.
In May 2020, the FDA approved ripretinib for adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib. Ripretinib serves as a fourth-line treatment option for patients with advanced GIST. ​
In January 2020, the FDA approved avapritinib for adult patients with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including the D842V mutation. This approval marked the first targeted therapy for this specific genetic mutation in GIST. ​
Key Gastrointestinal Stromal Tumors (GIST) companies such asJiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others are evaluating new drugs for Gastrointestinal Stromal Tumors (GIST) to improve the treatment landscape.
Promising Gastrointestinal Stromal Tumors (GIST) pipeline therapies in various stages of development include Famitinib, Nilotinib, THE-630, DS 6157, and others.

Gastrointestinal Stromal Tumors (GIST) Pipeline Analysis
The Gastrointestinal Stromal Tumors (GIST) pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Gastrointestinal Stromal Tumors (GIST) Market.

Categorizes Gastrointestinal Stromal Tumors (GIST) therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Gastrointestinal Stromal Tumors (GIST) drugs under development based on:

Stage of development

Gastrointestinal Stromal Tumors (GIST) Route of administration

Target receptor

Monotherapy vs. combination therapy

Gastrointestinal Stromal Tumors (GIST) Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Gastrointestinal Stromal Tumors (GIST) Licensing agreements

Funding and investment activities supporting future Gastrointestinal Stromal Tumors (GIST) market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Gastrointestinal Stromal Tumors (GIST) Emerging Drugs
Famitinib: Jiangsu Hengrui Medicine
Nilotinib: Novartis
THE-630: Theseus Pharmaceuticals
DS 6157: Daiichi Sankyo Company

Gastrointestinal Stromal Tumors (GIST) Companies

There are over 25 major companies currently engaged in developing treatments for Gastrointestinal Stromal Tumors (GISTs). Among these, Jiangsu Hengrui Medicine has a drug candidate that has reached the most advanced stage of clinical development-Phase III.

DelveInsight's report covers around 28+ products under different phases of Gastrointestinal Stromal Tumors (GIST) clinical trials like

Gastrointestinal Stromal Tumors (GIST) Late stage Therapies (Phase III)
Gastrointestinal Stromal Tumors (GIST) Mid-stage Therapies (Phase II)
Gastrointestinal Stromal Tumors (GIST) Early-stage Therapies (Phase I)
Gastrointestinal Stromal Tumors (GIST) Pre-clinical and Gastrointestinal Stromal Tumors (GIST) Discovery stage Therapies
Gastrointestinal Stromal Tumors (GIST) Discontinued & Inactive Therapies

Gastrointestinal Stromal Tumors (GIST) pipeline report provides the Gastrointestinal Stromal Tumors (GIST) therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Gastrointestinal Stromal Tumors (GIST) Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Gastrointestinal Stromal Tumors (GIST) Therapies and Key Gastrointestinal Stromal Tumors (GIST) Companies: Gastrointestinal Stromal Tumors (GIST) Clinical Trials and recent advancements https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Gastrointestinal Stromal Tumors (GIST) Pipeline Therapeutic Assessment
• Gastrointestinal Stromal Tumors (GIST) Assessment by Product Type
• Gastrointestinal Stromal Tumors (GIST) By Stage
• Gastrointestinal Stromal Tumors (GIST) Assessment by Route of Administration
• Gastrointestinal Stromal Tumors (GIST) Assessment by Molecule Type

Download Gastrointestinal Stromal Tumors (GIST) Sample report to know in detail about the Gastrointestinal Stromal Tumors (GIST) treatment market @ Gastrointestinal Stromal Tumors (GIST) Therapeutic Assessment https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Gastrointestinal Stromal Tumors (GIST) Current Treatment Patterns
4. Gastrointestinal Stromal Tumors (GIST) - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Gastrointestinal Stromal Tumors (GIST) Late-Stage Products (Phase-III)
7. Gastrointestinal Stromal Tumors (GIST) Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Gastrointestinal Stromal Tumors (GIST) Discontinued Products
13. Gastrointestinal Stromal Tumors (GIST) Product Profiles
14. Gastrointestinal Stromal Tumors (GIST) Key Companies
15. Gastrointestinal Stromal Tumors (GIST) Key Products
16. Dormant and Discontinued Products
17. Gastrointestinal Stromal Tumors (GIST) Unmet Needs
18. Gastrointestinal Stromal Tumors (GIST) Future Perspectives
19. Gastrointestinal Stromal Tumors (GIST) Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Gastrointestinal Stromal Tumors (GIST) Pipeline Reports Offerings: https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.